In Vitro Hb Production in Β-thalassemia Patients Is Not a Predictor of Clinical Responsiveness to Hydroxyurea
Abstract
Background: The hematologic response to hydroxyurea (HU) is varied among β-thalassemia (BT) patients. The BCL11A and SOX6 genes are involved in response to HU. This study aimed to investigate the in-vitro responsiveness of HU among BT major patients homozygote for IVSII-1G>A mutation and XmnI single nucleotide polymorphism (SNP) in order to find whether the in-vitro Hb concentration is a predictor of clinical (HU) responsiveness.
Methods: In this case-control study, twenty BT patients homozygote for IVSII-1G>A mutation and XmnI SNP from Thalassemia Research Center, Sari, Iran in 2015 were selected and categorized into two groups of 10 Responder (R) and 10 Non-Responder (NR) according to their clinical HU response. Ten healthy individuals as a control group were also selected. Hematopoietic erythroid progenitors were expanded from peripheral blood. Hb concentration was measured using photometry method. The flow cytometry and real-time PCR methods were applied for the analysis of cell surface markers (CD71 and CD235a) and gene expression (BCL11A and SOX6), respectively.
Results: R and NR groups produced higher amount of Basic Hb than C group in cell culture medium at day 14 (P<0.05). After HU treatment, in R group, Hb levels was significantly elevated in comparison to NR and C group (P<0.05). BCL11A expression was decreased after exposure to HU in all groups while SOX6 expression was only down-regulated in C group, and its expression was increased in R and NR groups after HU treatment.
Conclusion: Since different factors including wide networks of intracellular factors and individual differences between patients can affect response to HU in patients, the increasing Hemoglobin on culture medium alone cannot predict clinical responsiveness to that drug.
Schrier SL (2002). Pathophysiology of thalassemia. Curr Opin Hematol, 9:123–126.
Calzolari R1, Pecoraro A, Borruso V et al (2008). Induction of gamma-globin gene transcription by hydroxycarbamide in primary erythroid cell cultures from Lepore patients. Br J Haematol, 141(5):720-7.
Fibach E, Burke LP, Schechter AN, Noguchi CT, Rodgers GP (1993). Hydroxyurea increase fetal hemoglobin in cultured erythroid cells derived from normal individuals and patients with sickle cell anemia or β-thalassemia. Blood, 81:1630– 1635.
Ware RE (2010). How I use hydroxyurea to treat young patients with sickle cell anemia. Blood, 115(26):5300-11.
Ware RE, Despotovic JM, Mortier NA et al (2011). Pharmacokinetics, pharmacodynamics, and pharmacogenetics of hydroxyurea treatment for children with sickle cell anemia. Blood, 118(18):4985-91.
FabriceDanjou, Franco Anni, Renzo Galanello (2011). Beta-thalassemia: from genotype to phenotype. Haematologica, 96(11): 1573–1575.
Kanavakis E, Traeger-Synodinos J, Lafioniatis S et al (2004). A rare example that coinheritance of a severe form of beta-thalassemia and alpha-thalassemia interact in a "synergistic" manner to balance the phenotype of classic thalassemic syndromes. Blood Cells Mol Dis, 32(2):319-24.
Catherine Badens, Philippe Joly, Imane Agouti et al (2011). Variants in genetic modifiers of β-thalassemia can help to predict the major or intermedia type of the disease. Haematologica, 96(11): 1712–1714.
Yavarian M, Karimi M, Bakker E, Harteveld CL, Giordano PC (2004). Response to hydroxyurea treatment in Iranian transfusion-dependent beta-thalassemia patients. Haematologica, 89(10):1172-8.
Dedoussis GV, Mandilara GD, Boussiu M, Loutradis A (2000). HbF production in beta thalassaemia heterozygotes forthe IVS-II-1 G-->A beta(0)-globin mutation. Implication of the haplotype and the (G) gamma-158 C-->T mutation on the HbF level. Am J Hematol, 64(3):151-5.
Sankaran VG, Menne TF, Xu J et al (2008). Human fetal hemoglobin expression is regulated by the developmental stage-specific repressor BCL11A. Science, 322(5909):1839-42.
Xu J, Sankaran VG, Ni M et al (2010). Transcriptional silencing of {gamma}-globin by BCL11A involves long-range interactions andcooperation with SOX6. Genes Dev, 24(8):783-98.
Macrì S, Pavesi E, Crescitelli R et al (2015). Immunophenotypic Profiling of Erythroid Progenitor-Derived Extracellular Vesicles in Diamond-BlackfanAnaemia: A New Diagnostic Strategy. PLoS ONE, 10(9): e0138200.
Bakker WJ, Blazquez-Domingo M, Kolbus A et al (2004). FoxO3a regulates erythroid differentiation and induces BTG1, an activator of protein arginine methyl transferase 1. J Cell Biol, 164(2):175-84.
Livak KJ, Schmittgen TD (2001). Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2-[Delta][Delta]CT Method. Methods, 25(4):402-8.
Akbari MT1, Izadi P, Izadyar M et al (2008). Molecular basis of thalassemia intermedia in Iran. Hemoglobin, 32(5):462-70.
Pourfarzad F, von Lindern M, Azarkeivan A et al (2013). Hydroxyurea responsiveness in β-thalassemic patients is determined by the stress response adaptation of erythroid progenitors and their differentiation propensity. Haematologica, 98(5):696-704.
Yang YM1, Pace B, Kitchens D et al (1997). BFU-E colony growth in response to hy-droxyurea: correlation between in vitro and in vivo fetal hemoglobin induction. Am J Hematol, 56(4):252-8.
Watanapokasin Y1, Chuncharunee S, Sanmund D et al (2005). In vivo and in vitro studies of fetal hemoglobin induction by hydroxyurea in beta-thalassemia/hemoglobin E patients. Exp Hematol, 33(12):1486-92.
Khushnooma Italia, Farah Jijina, Rashid Merchant et al (2013). Comparison of in-vitro and in-vivo response to fetal hemoglobin production and γ-mRNA expression by hydroxyurea in Hemoglobinopathies. Indian J Hum Genet, 19(2): 251–258.
XiangJ, WuDC, ChenY, Paul-sonRF(2015).Invitro culture of stress erythroid progenitors identifies distinct progenitor populations and analogous humanprogenitors.Blood,125(11):1803-12.
Mabaera R, West RJ, Conine SJ et al (2008). A cell stress signaling model of fetal hemoglobin induction: what doesn't kill red blood cells may make themstronger. Exp Hematol, 36(9):1057-72.
Sankaran VG, Xu J, Ragoczy T et al (2009). Developmental and species-divergent globin switching are driven by BCL11A. Nature, 460(7259):1093-7.
Xu J, Sankaran VG, Ni M et al (2010). Transcriptional silencing of c-globin by BCL11A involves long-range interactions and cooperation with SOX6. Genes Dev, 24(8):783-98.
Schoenfelder S, Sexton T, Chakalova L et al (2010). Preferential associations between co-regulated genes reveal a transcriptional interactome in erythroid cells. Nat Genet, 42(1):53-61.
Bender MA, Bulger M, Close J, Groudine M (2000). Beta-Globin gene switching and DNase I sensitivity of the endogenous b-globin locus in mice do not require the locus control region. Mol Cell, 5(2):387-93.
Pule GD, Mowla S, Novitzky N, Wonkam A (2016). Hydroxyurea down-regulates BCL11A, KLF-1 and MYB through miRNA-mediated actions to induce γ-globinexpression: implications for new therapeutic approaches of sickle cell disease. ClinTransl Med, 5(1):15.
Flanagan JM, Steward S, Howard TA et al (2012). Hydroxycarbamide alters erythroid gene expression in children with sickle cell anaemia. Br J Haematol, 157:240-8.
Lefebvre V, Li P, de Crombrugghe B (1998). A new long form ofSox5 (L-Sox5), Sox6 and Sox9 are coexpressed in chondrogenesisand cooperatively activate the type II collagen gene. EMBO J, 17(19):5718-33.
Dumitriu B1, Dy P, Smits P, Lefebvre V (2006). Generation of miceharboring a Sox6 conditional null allele. Genesis, 44(5):219-24.
Cantù C, Ierardi R, Alborelli I et al (2011).Sox6 enhances erythroid differentiation in human erythroid progenitors. Blood, 117(13):3669-79.
Socolovsky M, Fallon AE, Wang S et al (1999). Fetal anemiaand apoptosis of red cell progenitors in Stat5a-/-5b-/- mice: a direct role forStat5 in Bcl-X (L) induction. Cell, 98(2):181-91.
Gregoli PA, Bondurant MC (1997). The roles of Bcl-X (L) and apopain in thecontrol of erythropoiesis by erythropoietin. Blood, 90(2):630-40.
Dumitriu B1, Bhattaram P, Dy P et al (2010). Sox6 is necessary for efficient erythropoiesis in adult mice under physiological and anemia-induced stress conditions. PLoS One, 5(8):e12088.
Rodgers GP, Dover GJ, Noguchi CT et al (1990). Hematologic Responses of Patients with Sickle Cell Disease to Treatment with Hydroxyurea. N Engl J Med, 322(15):1037–45.
Pecoraro A, Rigano P, Troia A, et al (2014). Quantification of HBG mRNA in primary erythroid cultures: prediction of the response to hydroxyurea in sickle cell and beta-thalassemia. Eur J Haematol, 92(1):66–72.
Musallam KM, Taher AT, Cappellini MD, et al (2013). Clincial Experience with Fetal Hemoglobin Induction Therapy in Paitents with β -thalassemia. Blood, 121(12):2199-212; quiz 2372.
| Files | ||
| Issue | Vol 46 No 7 (2017) | |
| Section | Original Article(s) | |
| Keywords | ||
| Hydroxyurea Thalassemia Hemoglobin | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
